BioAge Labs (NASDAQ:BIOA) Shares Gap Up – Still a Buy?

BioAge Labs, Inc. (NASDAQ:BIOA) gapped up prior to trading on Friday . The stock had previously closed at $16.25, but opened at $16.90. BioAge Labs shares last traded at $16.40, with a volume of 70,644 shares changing hands.

Wall Street Analyst Weigh In

BIOA has been the subject of a number of recent analyst reports. Oppenheimer initiated coverage on shares of BioAge Labs in a research report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, January 27th. Needham & Company LLC assumed coverage on BioAge Labs in a research report on Friday. They issued a “buy” rating and a $50.00 target price on the stock. Wall Street Zen upgraded BioAge Labs from a “sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Finally, Morgan Stanley set a $23.00 price target on BioAge Labs in a research report on Wednesday, February 4th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $46.25.

BioAge Labs Price Performance

The company has a market capitalization of $723.31 million, a PE ratio of -7.27 and a beta of 1.22. The stock’s 50 day simple moving average is $19.97 and its 200-day simple moving average is $12.89.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Tuesday, March 24th. The company reported ($0.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11. BioAge Labs had a negative net margin of 896.11% and a negative return on equity of 27.86%. The firm had revenue of $3.08 million during the quarter.

Insiders Place Their Bets

In related news, CFO Dov A. Md Goldstein sold 27,000 shares of the business’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total transaction of $531,900.00. Following the completion of the transaction, the chief financial officer directly owned 22,408 shares of the company’s stock, valued at $441,437.60. The trade was a 54.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Paul D. Rubin sold 7,433 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $18.75, for a total value of $139,368.75. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 267,540 shares of company stock worth $4,895,168 over the last 90 days. Corporate insiders own 20.82% of the company’s stock.

Hedge Funds Weigh In On BioAge Labs

Institutional investors and hedge funds have recently made changes to their positions in the stock. Jefferies Financial Group Inc. acquired a new stake in BioAge Labs in the second quarter valued at approximately $206,000. GSA Capital Partners LLP acquired a new position in BioAge Labs during the 3rd quarter worth approximately $181,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of BioAge Labs in the 2nd quarter valued at approximately $27,000. R Squared Ltd acquired a new stake in shares of BioAge Labs in the 3rd quarter valued at $154,000. Finally, Stonepine Capital Management LLC raised its holdings in shares of BioAge Labs by 202.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock valued at $624,000 after purchasing an additional 101,085 shares in the last quarter.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.